What it's for (Indications)
- Hydrocortisone + neomycin + polymyxin b + bacitracin ophthalmic preparations are indicated for the treatment of inflammatory ocular conditions where a superficial bacterial ocular infection or a risk of bacterial ocular infection exists.
- This combination therapy is particularly useful for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.
- Specific applications include chronic anterior uveitis, corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies, and certain postoperative inflammatory states.
- The inclusion of multiple antibiotics provides broad-spectrum coverage against common ocular pathogens.
- This formulation is prescribed when the inherent risks of steroid use are considered acceptable given the potential benefits in reducing inflammation and preventing or treating bacterial infection.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For ophthalmic solution formulations, the typical recommended dosage is to instill one or two drops into the conjunctival sac(s) of the affected eye(s) three to four times daily. For ophthalmic ointment formulations, a small ribbon of ointment (approximately 1/2 inch) should be applied into the conjunctival sac(s) three to four times daily, or as directed by an ophthalmologist. The frequency of application may be gradually decreased as the clinical condition improves. It is crucial to adhere strictly to the prescribed duration of treatment, which is often limited to prevent potential adverse effects associated with prolonged corticosteroid and antibiotic use. Patients should be advised on proper administration technique to avoid contamination of the applicator tip and ensure optimal drug delivery. Continuous re-evaluation by a healthcare professional is essential to monitor response and assess the need for continued therapy. |
Safety & Warnings
Common Side Effects
- Ophthalmic use of hydrocortisone + neomycin + polymyxin b + bacitracin can lead to a range of side effects, primarily due to the corticosteroid component.
- The most significant ocular adverse reactions include elevation of intraocular pressure (IOP) with possible development of glaucoma, optic nerve damage, and defects in visual acuity and fields.
- Posterior subcapsular cataract formation has been reported with prolonged corticosteroid use.
- Other common local effects are stinging, burning, irritation, itching, and foreign body sensation upon instillation.
- Allergic sensitization, particularly to neomycin, can occur, manifesting as itching, redness, or swelling.
- Secondary infection, especially fungal infections, can be facilitated by the immunosuppressive effects of corticosteroids.
- Additionally, thinning of the cornea or sclera can lead to perforation in the presence of pre-existing ocular surface disease.
- Systemic absorption resulting in Cushing's syndrome or adrenal suppression is extremely rare with topical ophthalmic application but possible with very prolonged and high-dose use.
Serious Warnings
- Black Box Warning: This specific combination ophthalmic product (hydrocortisone + neomycin + polymyxin b + bacitracin) does not carry a formal FDA Black Box Warning. However, due to the presence of a potent corticosteroid and broad-spectrum antibiotics, several **Serious Warnings** are critical for prescribers and patients to understand. Prolonged use of ophthalmic corticosteroids, even at therapeutic doses, can lead to increased intraocular pressure (IOP) with potential development of glaucoma, resulting in optic nerve damage, reduced visual acuity, and visual field defects. Patients on this medication for 10 days or longer require routine IOP monitoring. Corticosteroid use is also associated with the formation of posterior subcapsular cataracts. Furthermore, corticosteroids can suppress the host's immune response, leading to secondary ocular infections, especially exacerbation of viral (e.g., herpes simplex keratitis) and fungal infections; such infections can be masked by the steroid. Thinning of the cornea or sclera can occur, increasing the risk of globe perforation with topical corticosteroid application. Allergic sensitization, particularly to neomycin, is a potential risk and necessitates immediate discontinuation if observed.
- This combination ophthalmic product contains a corticosteroid and should not be used in the presence of active viral diseases of the cornea and conjunctiva, such as epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, or varicella, as corticosteroids can exacerbate these conditions significantly.
- Prolonged use of corticosteroids may also suppress the host immune response and lead to secondary ocular infections, including fungal infections.
- Fungal invasion should be suspected in any persistent corneal ulceration where a corticosteroid has been used, and appropriate culture should be performed.
- Extended use (typically beyond 10 days) requires regular monitoring of intraocular pressure, even if asymptomatic, due to the risk of steroid-induced glaucoma.
- Thinning of the cornea or sclera, often seen in conditions like rheumatoid arthritis or other connective tissue diseases, increases the risk of perforation with topical corticosteroids.
- Patients should be cautioned against wearing contact lenses during treatment.
- Allergic sensitization, particularly to neomycin, is a known risk and therapy should be discontinued immediately if signs of hypersensitivity develop.
How it Works (Mechanism of Action)
This combination ophthalmic preparation exerts its therapeutic effects through a multi-pronged approach targeting both inflammation and bacterial infection. Hydrocortisone, a potent corticosteroid, acts by inhibiting the release of inflammatory mediators. It stabilizes lysosomal membranes, inhibits leukocyte migration, reduces synthesis of prostaglandins and leukotrienes by inhibiting phospholipase A2, and reverses increased capillary permeability. This effectively suppresses inflammation, swelling, and itching. The antibiotic components, neomycin, polymyxin B, and bacitracin, provide broad-spectrum bactericidal activity. Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, thereby inhibiting bacterial protein synthesis. Polymyxin B, a polypeptide antibiotic, disrupts the integrity of the bacterial cytoplasmic membrane, leading to leakage of intracellular components and cell death. Bacitracin, another polypeptide antibiotic, interferes with bacterial cell wall synthesis by inhibiting dephosphorylation of lipid pyrophosphate, which is essential for peptidoglycan formation. Together, these antibiotics cover a wide range of Gram-positive and Gram-negative bacteria commonly implicated in ocular infections.
Commercial Brands (Alternatives)
No other brands found for this formula.